Company Information
Company Profile
Cash Flow Statement
Profit & Loss
Financial Position
Financial Ratio
Industry 科学研究和技术服务业
Company Introduction 2007年4月2日，裴迪南、戴龙签署《上海毕得医药科技有限公司章程》，决定共同出资设立上海毕得医药科技有限公司，公司注册资本为100万元，其中裴迪南认缴出资70万元，戴龙认缴出资30万元。根据裴迪南与戴岚签署的代持协议及双方意思表示，戴岚长期居住在国外，为便于办理注册登记、落实日常经营管理安排，戴岚委托裴迪南（戴岚姐姐的配偶）代为持有毕得有限70%的股权，戴岚为该代持股权的实际出资人，享有实际的股东权利并履行相应的股东义务；裴迪南受戴岚委托并根据戴岚的指示代为行使股东权利和履行股东义务。2007年4月27日，毕得有限经上海市工商行政管理局浦东新区分局登记成立，并核发《企业法人营业执照》。2020年9月30日，毕得有限召开2020年第四次股东会并作出决议，同意毕得有限整体变更为股份有限公司，以毕得有限截至2020年8月31日经中汇会计师审计的账面净资产354,243,256.09元折合股本4,500.00万股，每股面值为1元，超过折股部分的309,243,256.09元转入资本公积。2020年10月18日，公司召开创立大会暨第一次股东大会，整体变更为股份有限公司。2020年11月18日，毕得医药完成整体变更为股份有限公司的工商变更登记，取得了营业执照。 公司是一家以面向人民生命健康为基本价值观，聚焦于新药研发产业链前端，依托药物分子砌块的研发设计、生产及销售等核心业务，能够为新药研发机构提供结构新颖、功能多样的药物分子砌块及科学试剂等产品的高新技术企业、国家级专精特新“小巨人”企业。 公司的产品主要服务于药物靶点发现，苗头化合物合成及筛选，先导化合物发现、合成及优化，药物候选化合物发现等新药研发的关键环节。以药物构效和构性关系、药物化合物逆合成分析等理论为指导，公司多年密切跟踪新药物分子实体（NME）的动态，形成以药物分子砌块研发设计、定制化合成、分子结构确证、纯度检测及纯化等为代表的核心技术体系，构筑起种类全、规模大的药物分子砌块产品库，能够满足客户对药物分子砌块的高技术、多品类、微小剂量及多频次需求。公司具备向新药研发机构提供超过30万种结构新颖、功能多样的药物分子砌块的能力，其中常备药物分子砌块现货库超过7万种。
Main Business 聚焦于新药研发产业链前端，依托药物分子砌块的研发设计、生产及销售等
Legal Representative 戴岚
Top Executives
董事长：戴岚
董事：李涛,赵芸,王超,戴岚
独立董事：陶永平,刘志常,李健
Top 5 Shareholder
Shareholder name Nature Holding Date
戴岚限售股+流通A股32.64%30/09/2024
戴龙限售股14.42%30/09/2024
宁波欣曦创业投资合伙企业（有限合伙）流通A股5.52%30/09/2024
宁波兰旦创业投资合伙企业（有限合伙）限售股+流通A股4.74%30/09/2024
宁波鼎华永创创业投资合伙企业（有限合伙）流通A股2.50%30/09/2024
Company Secretary 李涛
Solicitors 北京国枫律师事务所
Auditors 中汇会计师事务所（特殊普通合伙）
Tel No 021-61601560
Fax No 021-61629029
Website www.bidepharmatech.com
Email ir@bidepharmatech.com
Company Address
Register: 上海市杨浦区翔殷路128号11号楼A座101室
Office: 上海市杨浦区翔殷路999号3幢6层
Listing Date 11/10/2022
Shares Capital
Shares Capital: 90,882,948
Total A Share: 90,882,948
Listed A Share: 43,234,172
Non-tradable A Share: 47,648,776
Other Share: 0
Total B Share: 0
Total H Share: 0
EPS(RMB)* ¥ 1.210
DPS(RMB)* ¥ 0.900
NBV Per Share(RMB)* ¥ 22.992
Market Capitalization(RMB) 1.821B
Smiley face Only Chinese content is avaliable
N
/
N
 : Eligible Stock for SH-HK Northbound trade (For all investors/ For institutional professional investors only)
N
 : Eligible Stock for SH-HK Ex-Northbound trade (sell only)
N
/
N
 : Eligible Stock for SZ-HK Northbound trade (For all investors/ For institutional professional investors only)
N
 : Eligible Stock for SZ-HK Ex-Northbound trade (sell only)
* Unadjusted Data
Information provided by: etnet
Terms and Conditions
Risk Disclosure:
The prices of securities may fluctuate, sometimes dramatically. The price of a security may move up or down, and may become valueless. It is as likely that losses will be incurred rather than profit made as a result of buying and selling securities. The information is for reference only, it does not constitute any offer, solicitation, recommendation, comment or any guarantee to the purchase or sale of any investment product or service. Customers should not make any investment decisions based on this information alone.
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources, Nanyang Commercial Bank Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.